 Hence FGFR3 represents a potential therapeutic target for the treatment of bladder cancer.Post-translational modification of FGFR3 occur in bladder cancer that do not occur in normal cells and can be targeted by immunotherapeutic antibodies.Achondroplasia is a dominant genetic disorder caused by mutations in FGFR3 that make the resulting protein overactive.